2型糖尿病强化血糖控制的获益与危害
该文综述了2型糖尿病强化与中等强度血糖控制的获益与危害。证据显示,强化血糖控制对患者重要的微血管和大血管结局无有意义获益,仅非致死性心肌梗死率降低;但强化控制增加严重低血糖风险,并通过多重用药、副作用和费用带来额外负担。心血管结局试验数据显示,特定类别降糖药物的心血管、肾脏和死亡率获益在很大程度上独立于其降糖效应。因此,2型糖尿病管理需要范式转变,从以血糖为中心转向确保充分糖尿病护理、使血糖目标与患者目标和情况相匹配、减少短期和长期并发症、减轻治疗负担并改善生活质量。
要点
- 与中等强度血糖控制相比,强化血糖控制对微血管和大血管结局无有意义获益,仅非致死性心肌梗死率降低。
- 强化血糖控制增加严重低血糖风险,并通过多重用药、副作用和费用带来额外负担。
- 心血管结局试验显示,特定类别降糖药物的心血管、肾脏和死亡率获益在很大程度上独立于其降糖效应。
- 2型糖尿病管理需从以血糖为中心转向以患者为中心,使血糖目标与患者目标和情况相匹配。
- 应优先确保充分糖尿病护理、减少短期和长期并发症、减轻治疗负担并改善生活质量,而非强化血糖控制。
适用人群与场景
- 2型糖尿病患者
- 绝大多数糖尿病患者为2型糖尿病
处置流程与药物剂量
- 血糖目标应与患者的目标和情况相匹配,而非优先追求强化血糖控制。
- 应确保充分糖尿病护理、减少短期和长期并发症、减轻治疗负担并改善生活质量。
研究设计与关键结果
- 综述指出,强化(对比中等强度)血糖控制对患者重要的微血管和大血管结局无有意义获益,仅非致死性心肌梗死率降低。
- 强化血糖控制增加严重低血糖风险,并通过多重用药、副作用和费用带来额外负担。
- 心血管结局试验数据显示,特定类别降糖药物的心血管、肾脏和死亡率结局可能改善,且很大程度上独立于其降糖效应。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,2型糖尿病管理需要范式转变,偏离以血糖为中心的观点,转向基于证据、以患者为中心的护理。
- 作者认为,不应优先强化血糖控制,而应关注确保充分糖尿病护理、使血糖目标与患者目标和情况相匹配、减少短期和长期并发症、减轻治疗负担并改善生活质量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Diabetes is a major and costly health concern worldwide, with high morbidity, disability, mortality, and impaired quality of life. The vast majority of people living with diabetes have type 2 diabetes. Historically, the main strategy to reduce complications of type 2 diabetes has been intensive glycemic control. However, the body of evidence shows no meaningful benefit of intensive (compared with moderate) glycemic control for microvascular and macrovascular outcomes important to patients, with the exception of reduced rates of non-fatal myocardial infarction. Intensive glycemic control does, however, increase the risk of severe hypoglycemia and incurs additional burden by way of polypharmacy, side effects, and cost. Additionally, data from cardiovascular outcomes trials showed that cardiovascular, kidney, and mortality outcomes may be improved with use of specific classes of glucose lowering drugs largely independently of their glycemic effects. Therefore, delivering evidence based, patient centered care to people with type 2 diabetes requires a paradigm shift and departure from the predominantly glucocentric view of diabetes management. Instead of prioritizing intensive glycemic control, the focus needs to be on ensuring access to adequate diabetes care, aligning glycemic targets to patients' goals and situations, minimizing short term and long term complications, reducing the burden of treatment, and improving quality of life.
参考来源
- Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, et al. Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ. 2019. PMID: 31690574. doi:10.1136/bmj.l5887
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。